$NRXP
NRX Pharmaceuticals, Inc. Stock $nrxp

$nrxp Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000143774924035289 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$2.411M
YoY Change		-3.33%
% of Gross Profit
Research & Development		$611.0K
YoY Change		-81.56%
% of Gross Profit
Depreciation & Amortization		$2.000K
YoY Change		-50.0%
% of Gross Profit
Operating Expenses		$3.022M
YoY Change		-47.97%
Operating Profit		-$3.022M
YoY Change		-47.97%
Interest Expense		$6.000K
YoY Change		-85.0%
% of Operating Profit
Other Income/Expense, Net		$1.399M
YoY Change		-650.79%
Pretax Income		-$1.623M
YoY Change		-73.23%
Income Tax
% Of Pretax Income
Net Earnings		-$1.623M
YoY Change		-73.23%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.15
Diluted Earnings Per Share		-$0.15
COMMON SHARES
Basic Shares Outstanding	12.09M	10.89M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$1.646M
YoY Change		-81.51%
Cash & Equivalents		$1.600M
Short-Term Investments
Other Short-Term Assets		$2.460M
YoY Change		-41.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables		$6.000K
Total Short-Term Assets		$4.106M
YoY Change		-68.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$356.0K
YoY Change		1595.24%
Total Long-Term Assets		$356.0K
YoY Change		1595.24%
TOTAL ASSETS
Total Short-Term Assets		$4.106M
Total Long-Term Assets		$356.0K
Total Assets		$4.462M
YoY Change		-65.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$4.866M
YoY Change		34.01%
Accrued Expenses		$4.489M
YoY Change		-5.05%
Deferred Revenue
YoY Change
Short-Term Debt		$634.0K
YoY Change
Long-Term Debt Due		$3.050M
YoY Change		-69.71%
Total Short-Term Liabilities		$20.30M
YoY Change		5.03%
LONG-TERM LIABILITIES
Long-Term Debt		$2.985M
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$2.985M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$20.30M
Total Long-Term Liabilities		$2.985M
Total Liabilities		$23.28M
YoY Change		20.47%
SHAREHOLDERS EQUITY
Retained Earnings		-$269.2M
YoY Change		8.19%
Common Stock		$11.00K
YoY Change		-86.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$18.82M
YoY Change
Total Liabilities & Shareholders Equity		$4.462M
YoY Change		-65.96%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$1.623M
YoY Change		-73.23%
Depreciation, Depletion And Amortization		$2.000K
YoY Change		-50.0%
Cash From Operating Activities		-$2.306M
YoY Change		-49.49%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		2.054M
YoY Change		-236.66%
NET CHANGE
Cash From Operating Activities		-2.306M
Cash From Investing Activities		0.000
Cash From Financing Activities		2.054M
Net Change In Cash		-252.0K
YoY Change		-95.85%
FREE CASH FLOW
Cash From Operating Activities		-$2.306M
Capital Expenditures		$0.00
Free Cash Flow		-$2.306M
YoY Change		-49.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	NRX Pharmaceuticals, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001719406
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11373246
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11373246
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8391940
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8391940
CY2023Q3	nrxp	Sale Of Stock And Warrants Issuance Costs SaleOfStockAndWarrantsIssuanceCosts	27000	usd
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95700000
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9600000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38302
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2844431
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1201 Orange Street, Suite 600
	dei	Entity Address City Or Town EntityAddressCityOrTown	Wilmington
	dei	Entity Address State Or Province EntityAddressStateOrProvince	DE
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19801
	dei	City Area Code CityAreaCode	484
	dei	Local Phone Number LocalPhoneNumber	254-6134
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12094094
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1646000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4595000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2460000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2289000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	4106000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6884000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	356000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	431000	usd
CY2024Q3	us-gaap	Assets Assets	4462000	usd
CY2023Q4	us-gaap	Assets Assets	7315000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4866000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4632000	usd
CY2024Q3	nrxp	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	9444000	usd
CY2023Q4	nrxp	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	4714000	usd
CY2024Q3	nrxp	Accrued Clinical Site Costs Current AccruedClinicalSiteCostsCurrent	403000	usd
CY2023Q4	nrxp	Accrued Clinical Site Costs Current AccruedClinicalSiteCostsCurrent	524000	usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3050000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	9161000	usd
CY2024Q3	us-gaap	Loans Payable Current LoansPayableCurrent	634000	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1902000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	17000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	20299000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19048000	usd
CY2024Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2985000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2024Q3	us-gaap	Liabilities Liabilities	23284000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	19048000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	250362000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241406000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-269195000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253147000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-18822000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11733000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4462000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7315000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	611000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3314000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5163000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10837000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2411000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2494000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10907000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12344000	usd
CY2024Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
CY2023Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	250000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	3022000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	5808000	usd
	us-gaap	Operating Expenses OperatingExpenses	16070000	usd
	us-gaap	Operating Expenses OperatingExpenses	23431000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3022000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5808000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16070000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23431000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	119000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	40000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	420000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	0	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	40000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	230000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	40000	usd
CY2024Q3	us-gaap	Loss On Contract Termination For Default LossOnContractTerminationForDefault	0	usd
CY2023Q3	us-gaap	Loss On Contract Termination For Default LossOnContractTerminationForDefault	0	usd
	us-gaap	Loss On Contract Termination For Default LossOnContractTerminationForDefault	849000	usd
	us-gaap	Loss On Contract Termination For Default LossOnContractTerminationForDefault	0	usd
CY2024Q3	nrxp	Fair Value Adjustment Of Convertible Debt FairValueAdjustmentOfConvertibleDebt	-1355000	usd
CY2023Q3	nrxp	Fair Value Adjustment Of Convertible Debt FairValueAdjustmentOfConvertibleDebt	359000	usd
	nrxp	Fair Value Adjustment Of Convertible Debt FairValueAdjustmentOfConvertibleDebt	-1014000	usd
	nrxp	Fair Value Adjustment Of Convertible Debt FairValueAdjustmentOfConvertibleDebt	2794000	usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-165000	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-26000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-174000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-27000	usd
CY2024Q3	nrxp	Gain Loss On Convertible Debt Redemption GainLossOnConvertibleDebtRedemption	-127000	usd
CY2023Q3	nrxp	Gain Loss On Convertible Debt Redemption GainLossOnConvertibleDebtRedemption	-0	usd
	nrxp	Gain Loss On Convertible Debt Redemption GainLossOnConvertibleDebtRedemption	-127000	usd
	nrxp	Gain Loss On Convertible Debt Redemption GainLossOnConvertibleDebtRedemption	-0	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1399000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-254000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2387000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1623000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-6062000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16048000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25818000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax	3000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax	0	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax	3000	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax	22000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-22000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1626000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6062000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16051000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25840000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.48
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10973697
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8194696
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10108859
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7411418
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11733000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	242000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	400000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6528000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-15069000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	97000	usd
CY2024Q2	nrxp	Apic Increase For Cost Recognition Contract Termination ApicIncreaseForCostRecognitionContractTermination	1336000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-7897000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-18391000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	104000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	37000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	829000	usd
CY2024Q3	nrxp	Reclassification Of Accumulated Other Comprehensive Income Upon Settlement Of Convertible Debt ReclassificationOfAccumulatedOtherComprehensiveIncomeUponSettlementOfConvertibleDebt	3000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1623000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-18822000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7409000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax	-106000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	695000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11039000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-284000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax	128000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	544000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	200000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8717000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2808000	usd
CY2023Q3	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	1171000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	351000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	782000	usd
CY2023Q3	nrxp	Adjustments To Additional Paid In Capital Increase For Settlement Of Deferred Offering Cost AdjustmentsToAdditionalPaidInCapitalIncreaseForSettlementOfDeferredOfferingCost	99000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-6062000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-6217000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16048000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25818000	usd
	us-gaap	Depreciation Depreciation	4000	usd
	us-gaap	Depreciation Depreciation	4000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	443000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1590000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	37000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-174000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-27000	usd
	nrxp	Fair Value Adjustment Of Convertible Debt Including Change In Fair Value From Credit Risk FairValueAdjustmentOfConvertibleDebtIncludingChangeInFairValueFromCreditRisk	-1011000	usd
	nrxp	Fair Value Adjustment Of Convertible Debt Including Change In Fair Value From Credit Risk FairValueAdjustmentOfConvertibleDebtIncludingChangeInFairValueFromCreditRisk	2794000	usd
	nrxp	Gain Loss On Convertible Debt Redemption GainLossOnConvertibleDebtRedemption	-127000	usd
	nrxp	Gain Loss On Convertible Debt Redemption GainLossOnConvertibleDebtRedemption	-0	usd
	nrxp	Debt Issuance Costs DebtIssuanceCosts	521000	usd
	nrxp	Debt Issuance Costs DebtIssuanceCosts	0	usd
	nrxp	Contract Costs ContractCosts	1336000	usd
	nrxp	Contract Costs ContractCosts	0	usd
	us-gaap	Loss On Contract Termination For Default LossOnContractTerminationForDefault	849000	usd
	us-gaap	Loss On Contract Termination For Default LossOnContractTerminationForDefault	0	usd
	nrxp	Noncash Litigation Expense NoncashLitigationExpense	0	usd
	nrxp	Noncash Litigation Expense NoncashLitigationExpense	250000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	100000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1554000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4949000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1654000	usd
	nrxp	Increase Decrease In Insurance Loan Payable IncreaseDecreaseInInsuranceLoanPayable	634000	usd
	nrxp	Increase Decrease In Insurance Loan Payable IncreaseDecreaseInInsuranceLoanPayable	0	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-106000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-466000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8539000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18465000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	-0	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	4000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	4800000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2288000	usd
	nrxp	Repayments Of Insurance Loans RepaymentsOfInsuranceLoans	-0	usd
	nrxp	Repayments Of Insurance Loans RepaymentsOfInsuranceLoans	474000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	521000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
	nrxp	Proceeds From Insurance Loans ProceedsFromInsuranceLoans	0	usd
	nrxp	Proceeds From Insurance Loans ProceedsFromInsuranceLoans	786000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2941000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	2059000	usd
	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	1171000	usd
	nrxp	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	4884000	usd
	nrxp	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	0	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1027000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	8122000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5590000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7317000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2949000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11152000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4595000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20054000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1646000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8902000	usd
	us-gaap	Interest Paid Net InterestPaidNet	374000	usd
	us-gaap	Interest Paid Net InterestPaidNet	646000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	nrxp	Stock Issued As Offering Costs StockIssuedAsOfferingCosts	188000	usd
	nrxp	Stock Issued As Offering Costs StockIssuedAsOfferingCosts	75000	usd
	nrxp	Stock Issued As Settlement Of Accrued Liability StockIssuedAsSettlementOfAccruedLiability	0	usd
	nrxp	Stock Issued As Settlement Of Accrued Liability StockIssuedAsSettlementOfAccruedLiability	250000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1600000	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	0
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the fair value of the convertible notes payable, fair value of warrant liabilities, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results <em style="font: inherit;"> may </em>differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Credit Risk and Off-Balance Sheet Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are <em style="font: inherit;">not</em> exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions <em style="font: inherit;"> may, </em>from time to time, exceed federally insured limits. As of <em style="font: inherit;"> September 30, 2024</em> the Company’s cash and cash equivalents balance within money market accounts was in excess of the U.S. federally insured limits by $1.2 million. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy.</p>
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	1185000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1078000	usd
CY2024Q3	nrxp	Prepaid Clinical Development Expense PrepaidClinicalDevelopmentExpense	848000	usd
CY2023Q4	nrxp	Prepaid Clinical Development Expense PrepaidClinicalDevelopmentExpense	871000	usd
CY2024Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	421000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	334000	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	6000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	6000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2460000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2289000	usd
CY2024Q3	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	4715000	usd
CY2023Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	0	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3573000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2686000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	324000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	835000	usd
CY2024Q3	nrxp	Accrued Research And Development Liability Current AccruedResearchAndDevelopmentLiabilityCurrent	592000	usd
CY2023Q4	nrxp	Accrued Research And Development Liability Current AccruedResearchAndDevelopmentLiabilityCurrent	1112000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	240000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	81000	usd
CY2024Q3	nrxp	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	9444000	usd
CY2023Q4	nrxp	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	4714000	usd
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95700000
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9600000
CY2024Q2	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	73040
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1700000
CY2024Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	20000
CY2024Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0.1	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3321499
CY2023	nrxp	Class Of Warrant Or Right Weighted Average Remaining Term ClassOfWarrantOrRightWeightedAverageRemainingTerm	P3Y10M28D
CY2023Q4	nrxp	Class Of Warrants Or Rights Weighted Average Exercise Price ClassOfWarrantsOrRightsWeightedAverageExercisePrice	23.01
CY2023Q4	nrxp	Class Of Warrants Or Rights Aggregate Intrinsic Value ClassOfWarrantsOrRightsAggregateIntrinsicValue	180000	usd
CY2024Q1	nrxp	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	718348
CY2024Q1	nrxp	Class Of Warrant Or Right Expired During Period ClassOfWarrantOrRightExpiredDuringPeriod	-5510
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4034337
CY2024Q1	nrxp	Class Of Warrant Or Right Weighted Average Remaining Term ClassOfWarrantOrRightWeightedAverageRemainingTerm	P3Y8M4D
CY2024Q1	nrxp	Class Of Warrants Or Rights Weighted Average Exercise Price ClassOfWarrantsOrRightsWeightedAverageExercisePrice	19.61
CY2024Q1	nrxp	Class Of Warrants Or Rights Aggregate Intrinsic Value ClassOfWarrantsOrRightsAggregateIntrinsicValue	807000	usd
CY2024Q2	nrxp	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	34903
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4069240
CY2024Q2	nrxp	Class Of Warrant Or Right Weighted Average Remaining Term ClassOfWarrantOrRightWeightedAverageRemainingTerm	P3Y5M8D
CY2024Q2	nrxp	Class Of Warrants Or Rights Weighted Average Exercise Price ClassOfWarrantsOrRightsWeightedAverageExercisePrice	19.47
CY2024Q2	nrxp	Class Of Warrants Or Rights Aggregate Intrinsic Value ClassOfWarrantsOrRightsAggregateIntrinsicValue	0	usd
CY2024Q3	nrxp	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	1349305
CY2024Q3	nrxp	Class Of Warrant Or Right Expired During Period ClassOfWarrantOrRightExpiredDuringPeriod	-90909
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5327636
CY2024Q3	nrxp	Class Of Warrant Or Right Weighted Average Remaining Term ClassOfWarrantOrRightWeightedAverageRemainingTerm	P3Y8M1D
CY2024Q3	nrxp	Class Of Warrants Or Rights Weighted Average Exercise Price ClassOfWarrantsOrRightsWeightedAverageExercisePrice	13.39
CY2024Q3	nrxp	Class Of Warrants Or Rights Aggregate Intrinsic Value ClassOfWarrantsOrRightsAggregateIntrinsicValue	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	264983
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.3
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	75000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	89546
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	175437
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.6
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	40000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	14000
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	161437
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.18
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	29604
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	131833
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.01
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	109399
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	24.13
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y1M6D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	104000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	351000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	443000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1590000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd

Files In Submission

Name	View Source	Status
0001437749-24-035289-index-headers.html	Edgar Link	pending
0001437749-24-035289-index.html	Edgar Link	pending
0001437749-24-035289.txt	Edgar Link	pending
0001437749-24-035289-xbrl.zip	Edgar Link	pending
ex_717342.htm	Edgar Link	pending
ex_717343.htm	Edgar Link	pending
ex_717344.htm	Edgar Link	pending
ex_717345.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nrxp-20240331x10q001.jpg	Edgar Link	pending
nrxp-20240331x10q002.jpg	Edgar Link	pending
nrxp-20240930.xsd	Edgar Link	pending
nrxp20240930_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
nrxp-20240930_cal.xml	Edgar Link	unprocessable
nrxp-20240930_def.xml	Edgar Link	unprocessable
nrxp-20240930_lab.xml	Edgar Link	unprocessable
nrxp-20240930_pre.xml	Edgar Link	unprocessable
nrxp20240930_10q_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NRXP
NRX Pharmaceuticals, Inc. Stock $nrxp

2024 Q4 Form 10-Q Financial Statement

#000143774924035289 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NRXP NRX Pharmaceuticals, Inc. Stock $nrxp

2024 Q4 Form 10-Q Financial Statement

#000143774924035289 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NRXP
NRX Pharmaceuticals, Inc. Stock $nrxp